These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22487487)

  • 1. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
    Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
    Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
    Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
    Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
    Roth TJ; Sheinin Y; Lohse CM; Kuntz SM; Frigola X; Inman BA; Krambeck AE; McKenney ME; Karnes RJ; Blute ML; Cheville JC; Sebo TJ; Kwon ED
    Cancer Res; 2007 Aug; 67(16):7893-900. PubMed ID: 17686830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
    J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.
    Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Tenta R; Koutsilieris M
    In Vivo; 2005; 19(5):911-20. PubMed ID: 16097446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kurahashi T; Miyake H; Hara I; Fujisawa M
    J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 over expression in prostate cancer promotes tumor cell progression.
    Yuan H; Wei X; Zhang G; Li C; Zhang X; Hou J
    J Urol; 2011 Sep; 186(3):1093-9. PubMed ID: 21784485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Gleave M; Fujisawa M
    Urology; 2006 Sep; 68(3):609-14. PubMed ID: 16979705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer. Further evidence for field effect in prostatic carcinogenesis.
    Mazzucchelli R; Barbisan F; Santinelli A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Hum Pathol; 2011 Dec; 42(12):1931-6. PubMed ID: 21676431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
    Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
    J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy.
    Amin A; Partin A; Epstein JI
    J Urol; 2011 Oct; 186(4):1286-90. PubMed ID: 21862072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies].
    Ojea Calvo A; Mosteiro Cerviño MJ; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; González Piñeiro A
    Arch Esp Urol; 2004 Oct; 57(8):805-16. PubMed ID: 15560269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.